EORTC Melanoma Group study selects AS15 adjuvant for active immunization with MAGE A3 protein for treatment of metastatic melanoma
29 May 2013
Gender plays a role in progression-free and disease-specific survival according to five EORTC studies in stage III-IV melanoma patients
23 May 2013
EORTC Melanoma Group investigating use of PEG-IFN- α-2b for patients with stage II ulcerated primary cutaneous melanoma
16 Jan 2013
Sylatron™ receives FDA approval based on the EORTC 18991 trial
28 Apr 2011
Abstracts accepted for the 2011 ASCO Annual Meeting
28 Apr 2011
Abstracts accepted for the 2010 ASCO Annual Meeting
26 May 2010
PEG-IFN- α-2b improves recurrence free survival in resected stage III melanoma, but health-related quality of life suffers
25 Jun 2009
Abstracts accepted for the 2009 ASCO Annual Meeting
4 May 2009
